Avidity Biosciences Inc (NASDAQ: RNA): A Competitive Analysis And Growth Prospects

EVTL

In the last trading session, 4.2 million shares of the Avidity Biosciences Inc (NASDAQ:RNA) were traded, and its beta was 0.99. Most recently the company’s share price was $26.26, and it changed around -$6.02 or -18.65% from the last close, which brings the market valuation of the company to $3.16B. RNA currently trades at a discount to its 52-week high of $56.00, offering almost -113.25% off that amount. The share price’s 52-week low was $21.51, which indicates that the current value has risen by an impressive 18.09% since then.

Avidity Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.07. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 0 recommended RNA as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight.

Avidity Biosciences Inc (NASDAQ:RNA) trade information

Instantly RNA has showed a red trend with a performance of -18.65% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 33.62 on recent trading dayincreased the stock’s daily price by 21.89%. The company’s shares are currently down -9.70% year-to-date, but still down -18.35% over the last five days. On the other hand, Avidity Biosciences Inc (NASDAQ:RNA) is -1.17% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $54.5, which translates to bulls needing to increase their stock price by 51.82% from its current value. Analyst projections state that RNA is forecast to be at a low of $50 and a high of $59.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -34.37%. Avidity Biosciences Inc earnings are expected to increase by -32.24% in 2025, but the outlook is positive 0.06% per year for the next five years.

RNA Dividends

Avidity Biosciences Inc’s next quarterly earnings report is expected to be released in June.

PRICE T ROWE ASSOCIATES INC /MD/, with 10.2093% or 10.92 million shares worth $445.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

T. Rowe Price New Horizons Fund, Inc. and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.43 shares worth $116.28 million, making up 3.67% of all outstanding shares. On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund held roughly 3.54 shares worth around $92.84 million, which represents about 2.93% of the total shares outstanding.